Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trialMatthew D. Galsky, Enrique Grande, Marina Mencinger et al.|The Lancet|2020Cited by 786
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint InhibitorsScott T. Tagawa, Petros Grivas, Arjun Vasant Balar et al.|Journal of Clinical Oncology|2021Cited by 530
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trialJoaquim Bellmunt, Thomas Powles, Maha Hussain et al.|The Lancet Oncology|2021Cited by 411
Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trialCharu Aggarwal, Nehal J. Lakhani, Amy Prawira et al.|Journal for ImmunoTherapy of Cancer|2022Cited by 140